Objective: To explore whether children diagnosed with type 1 diabetes during islet autoantibody surveillance through The Environmental Determinants of Diabetes in the Young (TEDDY) study retain greater islet function than children diagnosed through the community.
Conclusions: Higher C-peptide levels in TEDDY vs community-diagnosed children persist for at least 12 months following diabetes onset and appear to represent a shift in the disease process of about 6 months. Symptom-free diagnosis, reduction of DKA, and the potential for immune intervention with increased baseline C-peptide may portend additional long-term benefits of early diagnosis.
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| INTRODUCTION
Children participating in prospective studies, such as The Environmental Determinants of Diabetes in the Young (TEDDY), TrialNet, the Diabetes Autoimmunity Study in the Young (DAISY), BABYDIAB, and the Diabetes prediction in Skåne (DiPiS) study have been shown to have less diabetic ketoacidosis (DKA) and diabetes symptoms at diagnosis. [1] [2] [3] [4] [5] [6] TEDDY follows children with serial longitudinal analysis of islet autoantibodies to insulin, 7 GAD65, 8 IA-2, 9 and ZnT8, 10 and for diagnosis of type 1 diabetes, and offers close monitoring for autoantibody-positive subjects through hemoglobin A1c (HbA1c) and oral glucose tolerance tests. 11 Although multiple autoantibodypositive subjects have a more than 80% risk of developing diabetes within 15 years, the rate of progression of these high-risk individuals varies significantly, from a few months to more than 10 years. 12, 13 Preservation of C-peptide has been associated with lower risk of hypoglycemia and lower risk of long-term complications such as microalbuminuria and retinopathy. 14, 15 The decline in stimulated Cpeptide during the first year after the diagnosis of type 1 diabetes, as reported in the literature, is highly variable from 0% to 58%. [16] [17] [18] [19] Apart from early observational studies, 20 most of available C-peptide data are from the control arm of intervention trials. Data from subjects in TrialNet intervention studies (mean age 18 years) showed that 93% of type 1 diabetes patients still have detectable C-peptide at least 2 years from diagnosis. 21 Although these subjects were either placebo-treated subjects or subjects from intervention studies in which the intervention had no effect on beta-cell function, these study subjects had excellent diabetes control with mean HbA1c of 6.5% (48 mmol/mol) at entry and 7.6% (60 mmol/mol) after 2 years.
To date, only 1 small study has looked at the natural history of Cpeptide change in the general type 1 diabetes population. 22 In the latter study, the 9 children diagnosed through the DAISY study (mean age of diagnosis 12 years) had lower baseline HbA1c (6.5% vs 9.2%), lower insulin dose-adjusted HbA1c (IDAA1c: 7.4% vs 11.2%), and higher stimulated C-peptide at 60 minutes (2.5 ng/mL vs 1.6 ng/mL) when compared with 9 matched community children. However, those favorable patterns of IDAA1c and C-peptide were no longer apparent 1 year from diagnosis. Children followed before diabetes diagnosis within the DiPiS study had a lower HbA1c up to 2 years after diagnosis, compared with children diagnosed from the community. 4 In the T1D Exchange Clinic Network, the overall frequency of detectable non-fasting C-peptide was 29%, with higher frequency in those diagnosed above age 18; residual secretion was present in almost 1 of 3 individuals 3 or more years from diabetes diagnosis. 23 Although children are often diagnosed with type 1 diabetes with less severe presentation through TEDDY, 3, 6 it is not known whether this close monitoring also leads to better outcomes beyond diagnosis.
The goal of this study was to explore whether young children diagnosed with type 1 diabetes through the TEDDY study have higher Cpeptide levels and less insulin needs during the first year after diagnosis compared with control children diagnosed through the community. This is the first large, prospective, age-matched effort to analyze preservation of C-peptide in young children from the general population in comparison to the TEDDY cohort. 
| METHODS

| Study population
| Study visits
| Islet autoantibodies
Autoantibodies to GAD65, IA-2, and ZnT8 were measured in 2 reference laboratories by standard radiobinding assays. 27 For sites in the United States, all serum samples were assayed at the Barbara Davis
Center for Childhood Diabetes at the University of Colorado Denver.
In Europe, all sera were assayed at the University of Bristol, UK. Both laboratories have previously shown high-assay sensitivity and specificity, as well as concordance. 28 
| Statistical analysis
Data were analyzed using the Statistical Analysis System software (version 9.4; SAS Institute, Cary, North Carolina). For the comparison of characteristics at diagnosis of diabetes, diabetes management, and metabolic outcomes at each follow-up visit between cases and controls, paired analyses were used for confidence limits for continuous variables as the JDRF follow-up study has a 1:1 case-control matching design. C-Peptide was measured at time points 0, 15, 30, 60, 90, and 120 minutes. These timed values were combined using the trapezoidal rule to approximate the AUC; the reported value is the AUC divided by 120 minutes, which is an estimate of the mean of the C-peptide level over the 2-hour period. Both AUC and peak Cpeptide values were log-transformed to make the values more normally distributed, and paired tests with adjustment for the difference of age at diagnosis between matched cases and controls were performed. The mean curves of log C-peptide AUC for cases and controls during the first 12 months were examined using the generalized estimating equation (GEE) method, 29 with adjustment for age at diagnosis. An exchangeable correlation structure was assumed to account for the correlation of repeated measures of C-peptide AUC at multiple follow-up visits for each subject over time and the empirical standard error estimates were used. Ninety-five percent confidence limits and P-values from the GEE analyses were based on the Wald test. Data were assumed to be missing at random and the observed data were analyzed. In addition, rates of C-peptide decline during the first year were calculated, adjusting for HLA-DR3/4,DQB1*0302 and age at diagnosis as these potential confounding factors were different between TEDDY cases and community controls. IDAA1c, an alternate measure of residual beta-cell function, 30 was calculated as
. Two-tailed P-values less than 0.05 were considered to be statistically significant.
| RESULTS
Characteristics at diagnosis of diabetes of the 43 TEDDY and 43 community control children are described in Table 1 . TEDDY children diagnosed with diabetes often had no symptoms (58%) and none (0%) had DKA, compared with 98% with diabetes symptoms and 14% DKA in the community controls (P < 0.001 and P = 0.03, respectively). TEDDY children had lower mean HbA1c at diagnosis C-peptide levels during the first year after diabetes diagnosis between the TEDDY and community children are shown in Table 2 .
TEDDY children had higher AUC and peak C-peptide values than community controls throughout the first year postdiagnosis; these The reported frequency of DKA at diagnosis varies widely by country from 16% to 67%, and has been shown to be inversely associated with gross domestic product, latitude, and background incidence of type 1 diabetes. 31 While the incidence has decreased in some countries to below 20%, 32 the incidence of DKA in youth (<18 years) at diagnosis in Colorado has increased from 30% to 46% between 1998 and 2012. 33 In prospective studies such as TEDDY, DKA at onset is rare, with only 8% of very young children (median age: 2.3 years) presenting in DKA. 3, 6 In the TEDDY cohort overall, there has been a total of 15 children diagnosed with DKA: 8 of these children were diagnosed with diabetes below the age of 3; of the children presenting in DKA above the age of 3, 6 children did not have a TEDDY study visit within the last year before diabetes diagnosis and 1 subject was followed on a TEDDY long-distance protocol. In this study, 58% of TEDDY children (mean age 6 years) had no symptoms at diagnosis and none of them had DKA; only 14% of the community children had DKA, which is a low frequency of DKA for young general population children. TEDDY children in this study had 0% DKA, as all TEDDY children included in the JDRF follow-up study were over 3 years of age at diagnosis and had to have active follow up in TEDDY (ie TEDDY study visit during the previous 12 months before diabetes diagnosis). As this study involves multiple MMTTs during the first year postdiagnosis, it is possible that more medically committed community control families were enrolled into the study, This study appears to show a more durable improvement in endogenous islet function than seen before. A comparison of DAISY vs community subjects 22 showed lower baseline HbA1c, IDAA1c, and higher stimulated C-peptide at baseline in DAISY participants. At 6 months, C-peptide differences were no longer seen; and by 12 months, neither IDAA1c nor C-peptide was significantly different.
It is important to note that the DAISY children were older at diagnosis (mean age: 12.1 years) and that a modified MMTT was used with only 1 fasting and 1 stimulated C-peptide collected at 60 minutes after a standardized liquid meal Boost High Protein. In this younger and larger cohort of TEDDY children, differences in C-peptide, insulin doses, and IDAA1c stayed significant for at least the first year postdiagnosis.
Although TEDDY children have higher C-peptide values throughout the first year postdiagnosis, the loss of C-peptide appears to be parallel to that seen in community-diagnosed children, suggesting that TEDDY children are simply diagnosed earlier in the disease process. In an early study, rates of C-peptide decline from diabetes diagnosis were reported to be unrelated to age at diagnosis and were strikingly parallel in different age groups. 20 More recently, rates of Cpeptide decline have been highly variable with most of the data derived from the placebo arm of randomized-controlled trials assessing drug interventions in newly diagnosed subjects. 16, 17, 21, 34 Evaluation of C-peptide production after diagnosis in TrialNet showed a biphasic decline in C-peptide levels with a steeper slope of decline occurring during the first 12 months from diagnosis, then flattening between 12 and 24 months. 21 In this study, the decline in C-peptide production was much steeper in the first 6 months after diagnosis with flattening after 6 months in both the TEDDY and community children, similar to what was seen in the DAISY pilot study. 22 Higher initial C-peptide levels in children diagnosed through prospective monitoring studies are likely to give an improved window of opportunity for type 1 diabetes intervention trials. For example, in a report on 2-year outcomes in the Protégé trial of anti-CD3 therapy,
greater AUC mean C-peptide was significantly associated with a better response to drug therapy and better preservation of C-peptide over the next 2 years 35 .
Limitations of this study include differences in age of onset between the 2 cohorts, in spite of the study design to match on age.
As age is a known factor influencing C-peptide levels, C-peptide analyses were further adjusted by age. Although there were no selection criteria for community controls, it appears that this young group of children had a low frequency of DKA, which might result in a control group with greater residual C-peptide. If the community control group had more severe presentation at onset, the differences between the 2 groups might have been greater, as DKA at diagnosis has been associated with a lower frequency of partial remission ("honeymoon phase"). 36, 37 In summary, this study shows that earlier diagnosis of type 1 diabetes in TEDDY children is associated with higher stimulated levels of residual C-peptide, lower insulin doses, and lower IDAA1c during the first year postdiagnosis, compared to controls diagnosed with diabetes through the community. These higher C-peptide levels in TEDDY children appear to represent a shift in the disease process of about 6 months. Although the loss of C-peptide appears to be parallel, ongoing follow up of these children is important to help determine whether early symptom-free diagnosis of diabetes has longterm benefits.
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